{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T16:42:44Z","timestamp":1786207364640,"version":"build-2736575974"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Fakult\u00e4t Heidelberg der Universit\u00e4t Heidelberg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Urachal cancer is a rare but highly aggressive malignancy. This study examined current trends in the surgical management of urachal cancer in Germany.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material &amp; Methods<\/jats:title>\n                    <jats:p>The nationwide German hospital billing database (Destatis) and German quality reports were analyzed from 2006 to 2022. Identification of trends over time was performed using linear regression models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Between 2006 and 2022, a total of 2593 cases were treated for urachal cancer in Germany. In 530 cases, a partial (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a0413) or radical (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a0117) cystectomy was performed. The share of partial cystectomy for treatment of urachal cancer increased from 52% in 2006 to 74% in 2022 (p&lt;0.001). Radical cystectomy decreased from 48% in 2006 to 26% in 2022. Robotic-assisted partial cystectomy increased slightly from 9.7% in 2019 to 10.5% in 2022. The median age of patients undergoing partial cystectomy for urachal cancer increased from 57 \u00b1 15.35 years in 2006 to 62 \u00b1 12.59 years in 2022 (p&lt;0.001). Median length of stay after open partial cystectomy decreased from 14 days in 2006 to 9 days in 2022 (p&lt;0.001). Median length of stay for robotic-assisted partial cystectomy was 7 days in 2022. The mortality rate following partial cystectomy was 0.753%. The most common in-hospital complications associated with urachal cancer were hematuria in 1.19%, severe hemorrhage and hematoma in 0.96%, and paralytic ileus in 0.61%.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study demonstrates an increasing trend toward the use of partial cystectomy in the treatment of urachal cancer, along with a trend toward shorter hospital stays in recent years.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-026-19877-7","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T12:58:07Z","timestamp":1780318687000},"page":"8630-8635","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Surgical Management of Urachal Cancer in Germany: A Nationwide Analysis From 2006 to 2022"],"prefix":"10.1245","volume":"33","author":[{"given":"Luka","family":"Flegar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Eisenmenger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Reimold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Huber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christer","family":"Groeben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,1]]},"reference":[{"key":"19877_CR1","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1159\/000518028","volume":"106","author":"G Shao","year":"2022","unstructured":"Shao G, Xu C, Liu J, et al. Clinical, pathological, and prognostic analysis of urachal carcinoma. Urol Int. 2022;106:199\u2013208. https:\/\/doi.org\/10.1159\/000518028.","journal-title":"Urol Int"},{"key":"19877_CR2","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.juro.2012.06.020","volume":"188","author":"HM Bruins","year":"2012","unstructured":"Bruins HM, Visser O, Ploeg M, et al. The clinical epidemiology of urachal carcinoma: results of a large. Population Based Study J Urol. 2012;188:1102\u20137. https:\/\/doi.org\/10.1016\/j.juro.2012.06.020.","journal-title":"Population Based Study. J Urol"},{"key":"19877_CR3","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.urolonc.2016.04.012","volume":"34","author":"T Szarvas","year":"2016","unstructured":"Szarvas T, M\u00f3dos O, Niedworok C, et al. Clinical, prognostic, and therapeutic aspects of urachal carcinoma: a comprehensive review with meta-analysis of 1,010 cases. Urol Oncol Semin Orig Investig. 2016;34:388\u201398. https:\/\/doi.org\/10.1016\/j.urolonc.2016.04.012.","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"19877_CR4","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1016\/j.humpath.2015.07.021","volume":"46","author":"J Dhillon","year":"2015","unstructured":"Dhillon J, Liang Y, Kamat AM, et al. Urachal carcinoma: a pathologic and clinical study of 46 cases. Hum Pathol. 2015;46:1808\u201314. https:\/\/doi.org\/10.1016\/j.humpath.2015.07.021.","journal-title":"Hum Pathol"},{"key":"19877_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.euros.2022.02.009","volume":"39","author":"D Loizzo","year":"2022","unstructured":"Loizzo D, Pandolfo SD, Crocerossa F, et al. current management of urachal carcinoma: an evidence-based guide for clinical practice. Eur Urol Open Sci. 2022;39:1\u20136. https:\/\/doi.org\/10.1016\/j.euros.2022.02.009.","journal-title":"Eur Urol Open Sci"},{"key":"19877_CR6","doi-asserted-by":"publisher","first-page":"4273","DOI":"10.1002\/cam4.4786","volume":"11","author":"F Dursun","year":"2022","unstructured":"Dursun F, Lim K, Svatek RS, et al. Clinical outcomes and patterns of population-based management of urachal carcinoma of the bladder: An analysis of the national cancer database. Cancer Med. 2022;11:4273\u201382. https:\/\/doi.org\/10.1002\/cam4.4786.","journal-title":"Cancer Med"},{"issue":"3","key":"19877_CR7","doi-asserted-by":"publisher","first-page":"E57","DOI":"10.5489\/cuaj.5946","volume":"14","author":"Z Hamilou","year":"2020","unstructured":"Hamilou Z, North S, Canil C, et al. Management of urachal cancer: a consensus statement by the canadian urological association and genitourinary medical oncologists of Canada. Can Urol Assoc J. 2020;14(3):E57\u201364. https:\/\/doi.org\/10.5489\/cuaj.5946.","journal-title":"Can Urol Assoc J"},{"key":"19877_CR8","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.clgc.2021.03.002","volume":"19","author":"LE Stokkel","year":"2021","unstructured":"Stokkel LE, Stokkel MPM, Donswijk ML, et al. The diagnostic Value of FDG-PET\/CT for urachal cancer. Clin Genitourin Cancer. 2021;19:373\u201380. https:\/\/doi.org\/10.1016\/j.clgc.2021.03.002.","journal-title":"Clin Genitourin Cancer"},{"key":"19877_CR9","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.euros.2024.10.011","volume":"70","author":"L Flegar","year":"2024","unstructured":"Flegar L, Kipfer F, Durmus T, et al. Pyeloplasty and ureteral reconstruction surgery trends: a total population analysis in Germany from 2006 to 2022. Eur Urol Open Sci. 2024;70:116\u201323. https:\/\/doi.org\/10.1016\/j.euros.2024.10.011.","journal-title":"Eur Urol Open Sci"},{"key":"19877_CR10","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1159\/000509481","volume":"104","author":"T Hager","year":"2020","unstructured":"Hager T, Kraywinkel K, Szarvas T, et al. Urachal cancer in Germany and the USA: An RKI\/SEER population-based comparison study. Urol Int. 2020;104:803\u20139. https:\/\/doi.org\/10.1159\/000509481.","journal-title":"Urol Int"},{"key":"19877_CR11","doi-asserted-by":"publisher","first-page":"97","DOI":"10.4081\/rt.2016.6257","volume":"8","author":"DC Collins","year":"2016","unstructured":"Collins DC, Vel\u00e1zquez-Kennedy K, Deady S, et al. National incidence, management and survival of urachal carcinoma. Rare Tumors. 2016;8:97\u2013101. https:\/\/doi.org\/10.4081\/rt.2016.6257.","journal-title":"Rare Tumors"},{"issue":"Supplement 5","key":"19877_CR12","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000002603.07","volume":"207","author":"RS Flammia","year":"2022","unstructured":"Flammia RS, Chierigo F, Hoeh B, et al. PD42-07 Radical vs partial cystectomy for urachal carcinoma: a population-based analysis. J Urol. 2022;207(Supplement 5):e697. https:\/\/doi.org\/10.1097\/JU.0000000000002603.07.","journal-title":"J Urol"},{"key":"19877_CR13","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.3892\/ol.2014.2502","volume":"8","author":"D Chen","year":"2014","unstructured":"Chen D, Li Y, Yu Z, et al. Investigating urachal carcinoma for more than 15 years. Oncol Lett. 2014;8:2279\u201383. https:\/\/doi.org\/10.3892\/ol.2014.2502.","journal-title":"Oncol Lett"},{"key":"19877_CR14","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1159\/000365714","volume":"8","author":"K James","year":"2015","unstructured":"James K, Vasdev N, Mohan-S G, et al. robotic partial cystectomy for primary urachal adenocarcinoma of the urinary bladder. Curr Urol. 2015;8:183\u20138. https:\/\/doi.org\/10.1159\/000365714.","journal-title":"Curr Urol"},{"key":"19877_CR15","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1245\/s10434-019-08108-x","volume":"27","author":"L Flegar","year":"2020","unstructured":"Flegar L, Groeben C, Koch R, et al. Trends in renal tumor surgery in the United States and Germany between 2006 and 2014: organ preservation rate is improving. Ann Surg Oncol. 2020;27:1920\u20138. https:\/\/doi.org\/10.1245\/s10434-019-08108-x.","journal-title":"Ann Surg Oncol"},{"key":"19877_CR16","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1159\/000521605","volume":"106","author":"LE Stokkel","year":"2022","unstructured":"Stokkel LE, van de Kamp MW, Schaake EE, et al. Robot-assisted partial cystectomy versus open partial cystectomy for patients with urachal cancer. Urol Int. 2022;106:840\u20137. https:\/\/doi.org\/10.1159\/000521605.","journal-title":"Urol Int"},{"key":"19877_CR17","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1007\/s00345-022-04017-z","volume":"40","author":"L Flegar","year":"2022","unstructured":"Flegar L, Kraywinkel K, Zacharis A, et al. Treatment trends for muscle-invasive bladder cancer in Germany from 2006 to 2019. World J Urol. 2022;40:1715\u201321. https:\/\/doi.org\/10.1007\/s00345-022-04017-z.","journal-title":"World J Urol"},{"key":"19877_CR18","doi-asserted-by":"publisher","first-page":"221.e1","DOI":"10.1016\/j.urolonc.2024.03.011","volume":"42","author":"C Olah","year":"2024","unstructured":"Olah C, Kubik A, M\u00e1trai P, et al. Estimation of the incidence of urachal cancer: A systematic review and meta-analysis of registry-based studies. Urol Oncol Semin Orig Investig. 2024;42:221.e1-221.e7. https:\/\/doi.org\/10.1016\/j.urolonc.2024.03.011.","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"19877_CR19","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s00345-023-04737-w","volume":"42","author":"A Zacharis","year":"2024","unstructured":"Zacharis A, Reimold P, Aksoy C, et al. Trends in kidney transplantation and living donor nephrectomy in Germany: a total population analysis from 2006 to 2021. World J Urol. 2024;42:24. https:\/\/doi.org\/10.1007\/s00345-023-04737-w.","journal-title":"World J Urol"},{"key":"19877_CR20","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1159\/000496347","volume":"102","author":"C Groeben","year":"2019","unstructured":"Groeben C, Koch R, Baunacke M, et al. In-Hospital Outcomes after Radical Cystectomy for Bladder Cancer: Comparing National Trends in the United States and Germany from 2006 to 2014. Urol Int. 2019;102:284\u201392. https:\/\/doi.org\/10.1159\/000496347.","journal-title":"Urol Int"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19877-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-19877-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19877-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T15:48:50Z","timestamp":1786204130000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-19877-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":20,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["19877"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-19877-7","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]},"assertion":[{"value":"2 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Luka Flegar has received fees from Novartis, AstraZeneca, and Astellas outside the presented work. Mrs. Nicole Eisenmenger is founder and director of RI Innovation GmbH. Dr. Huber has received grants and non-financial support from Intuitive Surgical, Takeda, Janssen, Apogepha, and Coloplast outside the submitted work and is a member of the medical board of the Urological Foundation for Health. Dr. Groeben has received fees from Janssen and Merck and Bayer outside the presented work. All other authors declare that they have no conflicts of interest.","order":1,"name":"Ethics","label":"Disclosure","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki in its latest version. For data protection reasons, within the quality reports, the diagnostic (ICD) data or intervention numbers (OPS) with a number of \u22643 does not indicate the actual number, but the number 1. All data used are anonymized, so no further ethics committee approval was required. This article does not contain any studies with animals performed by any of the authors. Further, no written informed consent was required.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Ethics"}}]}}